Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Current Assets (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Current Assets data on record, last reported at $630.8 million in Q4 2025.

  • For Q4 2025, Current Assets rose 11.37% year-over-year to $630.8 million; the TTM value through Dec 2025 reached $630.8 million, up 11.37%, while the annual FY2025 figure was $630.8 million, 11.37% up from the prior year.
  • Current Assets reached $630.8 million in Q4 2025 per TGTX's latest filing, up from $599.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $664.0 million in Q2 2025 and bottomed at $168.3 million in Q4 2022.
  • Average Current Assets over 5 years is $397.4 million, with a median of $366.2 million recorded in 2021.
  • Peak YoY movement for Current Assets: skyrocketed 507.86% in 2021, then tumbled 55.49% in 2022.
  • A 5-year view of Current Assets shows it stood at $331.0 million in 2021, then crashed by 49.16% to $168.3 million in 2022, then surged by 88.94% to $317.9 million in 2023, then surged by 78.13% to $566.4 million in 2024, then grew by 11.37% to $630.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $630.8 million in Q4 2025, $599.8 million in Q3 2025, and $664.0 million in Q2 2025.